PAIN
Volume 142, Issue 3 , Pages 225-235 , April 2009

Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine

  • Jean-François Desaphy

      Affiliations

    • Sezione di Farmacologia, Dipartimento FarmacoBiologico, Facoltà di Farmacia, Università di Bari, Bari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 080 544 27 61; fax: +39 080 544 28 01.
    • These authors contributed equally to this work.
    • ,
  • Antonella Dipalma

      Affiliations

    • Sezione di Farmacologia, Dipartimento FarmacoBiologico, Facoltà di Farmacia, Università di Bari, Bari, Italy
    • These authors contributed equally to this work.
    • ,
  • Michela De Bellis

      Affiliations

    • Sezione di Farmacologia, Dipartimento FarmacoBiologico, Facoltà di Farmacia, Università di Bari, Bari, Italy
    • ,
  • Teresa Costanza

      Affiliations

    • Sezione di Farmacologia, Dipartimento FarmacoBiologico, Facoltà di Farmacia, Università di Bari, Bari, Italy
    • ,
  • Christelle Gaudioso

      Affiliations

    • CRN2M, CNRS UMR 6231, Université de la Méditerranée, CS80011.Bd Pierre Dramard, 13344 Marseille Cedex 15, France
    • ,
  • Patrick Delmas

      Affiliations

    • CRN2M, CNRS UMR 6231, Université de la Méditerranée, CS80011.Bd Pierre Dramard, 13344 Marseille Cedex 15, France
    • ,
  • Alfred L. George Jr.

      Affiliations

    • Division of Genetic Medicine, Department of Medicine, Vanderbilt University, 529 Light Hall, Nashville, TN 37232-0275, USA
    • ,
  • Diana Conte Camerino

      Affiliations

    • Sezione di Farmacologia, Dipartimento FarmacoBiologico, Facoltà di Farmacia, Università di Bari, Bari, Italy

Received 7 July 2008 ,Revised 18 December 2008 ,Accepted 9 January 2009.

References 

  1. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2:541–548
  2. Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol. 1983;81:613–642
  3. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 2004;108:237–247
  4. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology XLVIII. Nomenclature and structure–function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57:411–425
  5. Chahine M, Bennett PB, George AL, Horn R. Functional expression and properties of the human skeletal muscle sodium channel. Pflügers Arch. 1994;427:136–142
  6. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28:140–175
  7. Coste B, Crest M, Delmas P. Pharmacological dissection and distribution of NaN/Nav1.9, T-type Ca2+ currents, and mechanically activated cation currents in different populations of DRG neurons. J Gen Physiol. 2007;129:57–77
  8. Coste B, Osorio F, Padilla F, Crest M, Delmas P. Gating and modulation of presumptive NaV1.9 channels in enteric and spinal sensory neurons. Mol Cell Neurosci. 2004;26:123–134
  9. Cox JJ, Reimann F, Nicholas AK. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898
  10. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131:243–257
  11. Danze LK, Langdorf MI. Reversal of orphenadrine-induced ventricular tachycardia with physostigmine. J Emerg Med. 1991;9:453–457
  12. Desaphy J-F, De Luca A, Tortorella P, De Vito D, George AL, Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology. 2001;57:1849–1857
  13. Desaphy J-F, De Luca A, Didonna MP, George AL, Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol. 2004;554:321–334
  14. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain. 1992;48:261–268
  15. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007;117:3603–3609
  16. Elmalem J, Garnier R, Nguyen Huu Chieu R, Bismuth C, Efthymiou ML. Acute poisoning by orphenadrine. Ann Med Interne (Paris). 1985;136:640–645
  17. Fernández-Sánchez MT, Díaz-Trelles R, Groppetti A, Manfredi B, Brini AT, Biella G, et al. Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity. Amino Acids. 2002;23:31–36
  18. Gjerden P, Engelstad KS, Pettersen G, Slordal L. Fatalities caused by anticholinergic antiparkinsonian drugs. Analysis of findings in a 11-year national material. Tidsskr Nor Laegeforen. 1998;118:42–44Norwegian
  19. Gold RH. Treatment of low back syndrome with oral orphenadrine citrate. Curr Ther Res. 1978;23:271–276
  20. Hille B. Local anesthetic: hydrophilic and hydrophobic pathways for the drug receptor reaction. J Gen Physiol. 1977;69:497–515
  21. Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res. 1991;19:71–87
  22. Kim YS, Shin YK, Lee C, Song J. Block of sodium currents in rat dorsal root ganglion neurons by diphenhydramine. Brain Res. 2000;881:190–198
  23. Klugbauer N, Lacinova L, Flockerzi V, Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 1995;14:1084–1090
  24. Kornhuber J, Parsons CG, Hartmann S, Kamolz S, Thome J, Riederer P. Orphenadrine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Trans Gen Sect. 1995;2:237–246
  25. Kuo CC, Huang RC, Luo BS. Inhibition of Na+ current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol. 2000;57:135–143
  26. Labout JJM, Thijssen CT, Keijser GGJ, Hespe W. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol. 1982;21:343–350
  27. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol. 2003;13:291–297
  28. Lee SY, Oh HJ, Kim JW, Kim YG, Moon CJ, Lee EH. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS). J Chromatogr B Anal Technol Biomed Life Sci. 2006;839:118–123
  29. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs Aging. 2005;22:731–740
  30. Legroux-Crespel E, Sassolas B, Guillet G, Kupfer I, Drupe D, Misery L. Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol. 2003;130:429–433
  31. Lossin C, Wang DW, Rhodes TH, Vanoye CG, George AL. Molecular basis of an inherited epilepsy. Neuron. 2002;34:877–884
  32. Luzza F, Raffa S, Saporito F, Oreto G. Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. Int J Clin Pract. 2006;60:606–608
  33. Maingret F, Coste B, Padilla F, Clerc N, Crest M, Korogod SM, et al. Inflammatory mediators increase Nav1.9 current and excitability in nociceptors through a coincident detection mechanism. J Gen Physiol. 2008;131:211–225
  34. Maruyama H, Nakamoto M, Matsunomi T, Zheng T, Nakata Y, Wood JN, et al. Electrophysiological characterization of the tetrodotoxin-resistant Na+ channel, Nav(1.9), in mouse dorsal root ganglion neurons. Pflugers Arch. 2004;449:76–87
  35. Priest BT, Murphy BA, Lindia JA, Diaz C, Abbadie C, Ritter AM, et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA. 2005;102:9382–9387
  36. Priest BT, Kaczorowski GJ. Blocking sodium channels to treat neuropathic pain. Exp Opin Ther Targets. 2007;11:291–306
  37. Pubill D, Canudas AM, Pallàs M, Sureda FX, Escubedo E, Camins A, et al. Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol. 1999;51:307–312
  38. Pullen GP, Best NR, Maguire J. Anticholinergic drug abuse: a common problem?. Br Med J. 1984;289:612–613
  39. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na channels by local anesthetic. Science. 1994;265:1724–1728
  40. Roza C, Laird JM, Souslova V, Wood JN, Cervero F. The tetrodotoxin-resistant Na+ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol. 2003;550:921–926
  41. Rumore MM, Schlichting DA. Analgesic effects of antihistaminics. Life Sci. 1985;36:403–416
  42. Schaffler K, Reitmeir P. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory-evoked potentials obtained from capsaicin-irritated skin in healthy volunteers. Arzneimittelforschung. 2004;54:673–679
  43. Scholz EP, Konrad MF, Weiss DL, Zitron E, Kiesecker C, Bloehs R, et al. Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn-Schmiedeberg’s Arch Pharmacol. 2007;376:275–284
  44. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In:  Hardman JG,  Limbird LE,  Molinoff PB,  Ruddon RW,  Goodman Gilman A editor. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed.. New York: McGraw-Hill; 1995;p. 503–519
  45. Sweeney PJ. Parkinson’s disease: managing symptoms and preserving function. Geriatrics. 1995;509:24–31
  46. Syvälahti EK, Kunelius R, Laurén L. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988;62:90–94
  47. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci. 2000;21:52–56
  48. Wang DW, George AL, Bennett PB. Comparison of heterologously expressed human cardiac and skeletal muscle sodium channels. Biophys J. 1996;70:238–245
  49. Waxman SG. Nav1.7, its mutations, and the syndromes that they cause. Neurology. 2007;69:505–507
  50. Wright SN, Wang SY, Kallen RG, Wang GK. Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Biophys J. 1997;73:779–788

PII: S0304-3959(09)00039-6

doi: 10.1016/j.pain.2009.01.010

PAIN
Volume 142, Issue 3 , Pages 225-235 , April 2009

Article Tools

* Image Usage & Resolution